Atox Bio is a late stage, critical care immunotherapy company focusing on acute, life threatening, conditions with significant unmet need. We are developing Reltecimod, an immunomodulator, which is designed to enhance resolution of organ failure in conditions associated with severe, acute inflammation such as Necrotizing Soft Tissue Infection (NSTI) and sepsis.
